Miguel Martin

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Miguel Martin
Oct 28, 2024, 08:58 | Insight
Five articles suggested by Yüksel Ürün
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey.…
Oct 18, 2024, 12:10 | Blog
From One-Size-Fits-All to Personalized Treatment: An article by Marleen Kok et al.
Maryam Lustberg shared on LinkedIn: "From One-Size-Fits-All to Personalized Treatment: Challenges and Potential Solutions. Opportunities…
Aug 18, 2024, 07:29 | Blog,Opinion
Paolo Tarantino: Do all patients with TNBC need 5 neoadjuvant drugs + 1 year of IO?
Paolo Tarantino shared a post on X about recent paper by Marleen Kok et al., titled…
Jul 27, 2024, 22:17 | Insight
Commentary led by Marleen Kok highlights all questions in early TNBC post-KN522
Erika Hamilton shared on X: "This commentary led by Marleen Kok highlights all the pertinent…
Jul 26, 2024, 00:03 | Blog
Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522
Elisa Agostinetto shared on X: "Out in JCO a must-read by Marleen Kok on the…
Jul 25, 2024, 08:58 | Insight
Marleen Kok: How do we get from one-size-fits-all to personalized treatment for TNBC
Marleen Kok, Breast Medical Oncologist at the Netherlands Cancer Institute, shared on X: "Today from…
Jul 22, 2024, 23:09 | Blog
Aleix Prat: TNBC-DX - new genomic profiling tool for the treatment of early-stage triple-negative breast cancer (TNBC)
Aleix Prat, Director of Cancer Institute and Blood Disorders at Clinical Hospital of Barcelona, shared…
Apr 29, 2024, 14:18 | Drugs
Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer
Matthew Goetz, Professor of Oncology and Pharmacology at Mayo Clinic, shared on LinkedIn: “An important…
All: 8 Posts: 1 - 100
Special Coverage